NEW YORK, Nov. 26, 2024
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.69% during the forecast period. Rising global burden of diabetes is driving market growth, with a trend towards increasing growth opportunities in emerging markets. However, stringent regulatory guidelines poses a challenge.Key market players include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc..
Advertisement
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF
Gastroparesis Drugs Market Scope
Advertisement
Report Coverage
Details
Base year
2023
Historic period
2018 - 2022
Forecast period
2024-2028
Growth momentum & CAGR
Accelerate at a CAGR of 3.69%
Market growth 2024-2028
USD 1.42 billion
Market structure
Fragmented
YoY growth 2022-2023 (%)
3.53
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 37%
Key countries
US, Germany, UK, China, and Japan
Key companies profiled
Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc.
Market Driver
The Gastroparesis Drugs Market is witnessing significant growth due to the rising prevalence of Gastroparesis, a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx's tradipitant is a promising innovation, joining metoclopramide, metopimazine, deudomperidone, and prokinetic agents in symptom management. Diabetes, lifestyles (alcohol consumption, tobacco), and surgical procedures contribute to gastroparesis. Diabetic cases, especially those with autonomic neuropathy, are a major focus. Companies like Evoke Pharma and ANI Pharmaceuticals are leading the market with FDA-cleared drugs. GI symptoms like nausea, vomiting, and abdominal discomfort lead to nutrient absorption complications. Erythromycin and antiemetics are common treatments, but new clinical trials explore alternatives like Reglan. PubMed Central hosts numerous studies on gastroparesis, including Acute cholecystitis and Acute pancreatitis. Innovative drugs, such as those addressing blood sugar regulation, enteral nutrition, and feeding intolerance, are in development. Hospitals and specialized care centers offer surgical interventions for severe cases.
Vendors in the gastrointestinal drugs market are expanding their businesses in emerging economies to tap into the growing number of individuals with undiagnosed and untreated gastrointestinal disorders. For instance, the incidence and prevalence of chronic gastrointestinal disorders in Asia, particularly in China and India, have been rising. To capitalize on this trend, companies are increasing their R&D efforts and manufacturing capacities in these regions. Abbott, for example, is expanding its R&D teams in Brazil, India, and China to enhance its product offerings and launch new solutions. This strategic expansion will create significant revenue opportunities and strengthen the market's growth trajectory.
Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!
Discover how AI is revolutionizing market trends- Get your access now!
This gastroparesis drugs market report extensively covers market segmentation by
1.1 Prokinetic agents- Prokinetic drugs play a significant role in managing gastroparesis, a condition characterized by delayed stomach emptying. These medications, such as metoclopramide and domperidone, are popular due to their ability to address the fundamental cause of the condition. While not all prokinetic agents produce a corresponding improvement in stomach emptying, they are effective in alleviating symptoms like nausea, vomiting, and early satiety. Other recent drugs, including ghrelin, motilin, 5-HT4 receptor agonists, and dopamine receptor agonists, are being studied for their potential in gastroparesis treatment. The use of prokinetic agents for symptoms like constipation, caused by decreased motility in the distal GI tract, also increases their demand and drives market growth during the forecast period. Ani Pharmaceuticals offers Reglan, a metoclopramide formulation, for gastroparesis treatment in the US.
Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics
Gastroparesis is a chronic condition characterized by delayed emptying of the stomach, leading to various digestive disruptions such as nausea, vomiting, and abdominal pain. Neurogastrx's tradipitant is a promising new drug for gastroparesis treatment, while metopimazine, deudomperidone, and metoclopramide are common antiemetics used for symptom management. Evoke Pharma and ANI Pharmaceuticals are among the companies involved in gastroparesis drug development. Diabetes, lifestyles including alcohol consumption and tobacco use, and certain medications like Erythromcin can trigger gastroparesis. Innovative drugs under clinical trials aim to address the underlying causes and improve patient outcomes. However, these drugs may carry risks such as liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis. Antiemetics like Reglan have been linked to Tardive Dyskinesia, a serious side effect. Clinical trials are ongoing to evaluate the safety and efficacy of new treatments for gastroparesis.
Gastroparesis is a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx's tradipitant is a promising innovative drug under development for gastroparesis treatment. Other prokinetic agents like metopimazine, deudomperidone, and metoclopramide are commonly used for symptom management. Evoke Pharma and ANI Pharmaceuticals are among the companies involved in gastroparesis drug development. Diabetes, lifestyles (alcohol consumption, tobacco use), and certain medications can trigger gastroparesis. Symptoms include nausea, vomiting, abdominal discomfort, and nutrient absorption complications. Diabetic gastroparesis is a common complication in diabetic cases. Hospitals and specialized care centers offer surgical interventions for severe cases, including FDA-cleared procedures. PubMed Central hosts numerous studies on gastroparesis, its causes, and potential treatments. Other conditions like Acute cholecystitis and Acute pancreatitis can also cause gastroparesis. Antiemetics like Erythromycin and Reglan are sometimes used to manage symptoms. Clinical trials are ongoing to explore new treatment options. Autonomic neuropathy is a potential cause of gastroparesis. Prokinetic agents help promote stomach contractions and hinder hindering digestion. Enteral nutrition and feeding intolerance are common complications.
1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation
7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [email protected]: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/gastroparesis-drugs-market-to-grow-by-usd-1-42-billion-2024-2028-diabetes-burden-boosts-growth-ai-impact-on-market-trends---technavio-302315581.html
SOURCE Technavio
